Skip to Content
Merck
  • 16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovis.

16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovis.

Antimicrobial agents and chemotherapy (2014-11-19)
E Amram, I Mikula, C Schnee, R D Ayling, R A J Nicholas, R S Rosales, S Harrus, I Lysnyansky
ABSTRACT

Mycoplasma bovis isolates with decreased susceptibilities to tetracyclines are increasingly reported worldwide. The acquired molecular mechanisms associated with this phenomenon were investigated in 70 clinical isolates of M. bovis. Sequence analysis of the two 16S rRNA-encoding genes (rrs3 and rrs4 alleles) containing the primary binding pocket for tetracycline (Tet-1 site) was performed on isolates with tetracycline hydrochloride MICs of 0.125 to 16 μg/ml. Mutations at positions A965T, A967T/C (Escherichia coli numbering) of helix 31, U1199C of helix 34, and G1058A/C were identified. Decreased susceptibilities to tetracycline (MICs, ≥2 μg/ml) were associated with mutations present at two (A965 and A967) or three positions (A965, A967, and G1058) of the two rrs alleles. No tet(M), tet(O), or tet(L) determinants were found in the genome of any of the 70 M. bovis isolates. The data presented correlate (P<0.0001) the mutations identified in the Tet-1 site of clinical isolates of M. bovis with decreased susceptibility to tetracycline.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Tetracycline hydrochloride, meets USP testing specifications
Sigma-Aldrich
Tetracycline hydrochloride, powder, BioReagent, suitable for cell culture
Supelco
Tetracycline hydrochloride, VETRANAL®, analytical standard
Supelco
Tetracycline hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material